- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02716363
Rotational Atherectomy for Calcified lEsion By Smart Angioplasty Research Team (SMART-RACE)
February 7, 2018 updated by: Hyeon-Cheol Gwon, Samsung Medical Center
SMart Angioplasty Research Team: A Multi-center, Open Study to Evaluation the Efficacy and Safety of Rotational Atherectomy With Drug Eluting Stent for Calcified LEsion in Korea (SMART-RACE) Trial
Current guidelines recommend the use of rotational atherectomy (RA) for preparation of heavily calcified or severely fibrotic lesions that cannot be crossed by a balloon or adequately dilated before planned stenting (bailout situations).
RA emerged in the 1990s as one of several tools to treat luminal obstruction via physical removal of plaque.
Although initially explored as an alternative to balloon angioplasty, RA has shown favorable acute results in facilitating stent delivery and adequate expansion, particularly those affected by heavy calcification.Drug-eluting stents (DES) have substantially reduced re-stenosis rates in randomized clinical trials evaluating simple de novo coronary artery lesions and have also shown favorable results when implanted in complex lesions and patients, but higher event rates are observed when treating such subsets compared with simple lesions even with newer generation DES.
However, there are limited data on evaluating the safety and effectiveness of RA followed by DES implantation for heavily calcified lesions in contemporary practice.
Recent randomized controlled trial shows that RA before paclitaxel eluting stent implantation as first generation DES was not superior to paclitaxel eluting stent implantation without prior RA in reducing the primary endpoint of in-stent late luminal loss at 9 months, indicating that RA does not increase the efficacy of DES in patients with moderate to severe calcified lesions.
However, there were only 15 (12.5%) crossovers from standard therapy to rotablation because of failure of balloon or stent delivery or suboptimal balloon expansion despite the use of a noncompliant balloon.
Accordingly, procedural and fluoroscopy times were longer in the elective RA and procedural complications occurred equally in both elective RA and bailout RA.
These findings might cause by a substantial portion of enrolled population have moderate calcified lesions, but not severe calcified lesions.
In particular, everolimus-eluting stent (EES) as newer generation DES could act synergistically in heavily calcified lesions as RA could avert stent coating damage and EES could effectively suppress neointimal proliferation.
Therefore, we compare in-hospital and long-term efficacy or safety of elective RA versus bailout RA and low-volume operator versus high-volume operator in patients with severe calcified lesions treated with EES.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
500
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Recruiting
- Hyoen-Cheol Gwon, MD,PhD
-
Contact:
- Hyoen-Cheol Gwon, MD,PhD
- Phone Number: 82-2-3410-3418
- Email: hcgwon@skku.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject must be at least 19 years of age
- Angiographically proven coronary artery disease
- Patients underwent Rotational Atherectomy
- He/she or his/her legally authorized representative provides written informed consent
- Target lesion(s) must be located in a native coronary artery with visually estimated diameter of ≥ 2.25 mm and ≤ 4.25 mm
Exclusion Criteria:
- Cardiac arrest before the procedure
- Pregnancy or breast feeding
- Thrombotic lesion
- Saphenous vein graft
- Unprotected left main lesion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Device : Rotablator
We compare in-hospital and long-term efficacy or safety of elective Rotational Atherectomy versus bailout Rotational Atherectomy and low-volume operator versus high-volume operator in patients with severe calcified lesions treated.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
A composite procedure-related complication
Time Frame: 2 years
|
cardiac death, peri-procedural myocardial infarction (CK-MB rise > X10 URL), coronary perforation, cardiopulmonary resuscitation, hemodynamic support (IABP, PCPS), or emergency surgery
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Procedure duration
Time Frame: from guiding catheter to final angiography, an average of 1 day
|
from guiding catheter to final angiography, an average of 1 day
|
|
|
Fluoroscopy time
Time Frame: from guiding catheter to final angiography, an average of 1 day
|
from guiding catheter to final angiography, an average of 1 day
|
|
|
Target vessel failure
Time Frame: 1,6 and 12months
|
Defined as a composite of cardiac death, myocardial infarction , or target vessel revascularization
|
1,6 and 12months
|
|
Final in-stent minimal lumen area by IntraVascular UltraSound
Time Frame: 1,6 and 12months
|
1,6 and 12months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2015
Primary Completion (Anticipated)
August 31, 2020
Study Completion (Anticipated)
August 31, 2020
Study Registration Dates
First Submitted
March 7, 2016
First Submitted That Met QC Criteria
March 17, 2016
First Posted (Estimate)
March 23, 2016
Study Record Updates
Last Update Posted (Actual)
February 9, 2018
Last Update Submitted That Met QC Criteria
February 7, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-06-157
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Infirmerie Protestante de LyonRecruitingCoronary Artery Bypass | Coronary Artery Disease(CAD) | Off Pump Coronary Artery Bypass Surgery | Hemodynamic Optimization | Hemodynamic Management | Off Pump Coronary Artery Bypass Graft | Coronary Artery Disease With Need for Bypass Surgery | NoradrenalineFrance
-
Shanghai Bluesail Boyuan Medical Technology Co....Not yet recruitingCoronary Artery Disease | Coronary Artery Calcification | Severe Coronary Artery DiseaseChina
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioCompletedCoronary Artery Disease (CAD) | Atherosclerosis of Coronary ArteryItaly
-
Scitech Produtos Medicos SANot yet recruitingCoronary Artery Disease (CAD) | Multivessel Coronary Artery Disease | Complex Coronary Lesions | Calcific Coronary Arteriosclerosis | Small Vessel Ischemic Disease | Stenosis CoronaryBrazil
-
Istanbul Mehmet Akif Ersoy Educational and Training...Bakirkoy Dr. Sadi Konuk Research and Training Hospital; Ege University; Istanbul... and other collaboratorsActive, not recruitingCoronary Artery Disease (CAD) | Coronary Bifurcation Lesion | Left Main Coronary Artery StenosisTurkey (Türkiye)
-
University Medical Centre LjubljanaRecruitingCoronary Artery Disease With Myocardial InfarctionSlovenia
-
EBI Anti Sepsis BVCR2O B.V.Not yet recruitingCoronary Artery Disease (CAD) | Coronary Artery Bypass Graft Surgery(CABG)United States, Netherlands, Belgium, United Kingdom
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Mahidol UniversityThe Princess Mantarop Kamalas Foundation, The Nurses' Association of Thailand and other collaboratorsActive, not recruitingCoronary Artery Disease (CAD) | Postoperative Recovery | Coronary Artery Bypass Graft (CABG)Thailand
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
Clinical Trials on Rotational Atherectomy by Rotablator
-
Columbia UniversityCompletedCoronary Artery Disease (CAD)United States
-
Shanghai MicroPort Rhythm MedTech Co., Ltd.Enrolling by invitationCalcification of Coronary ArteryChina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaCompletedCoronary VesselsKorea, Republic of
-
Xijing HospitalCompletedCoronary Artery DiseaseChina
-
National Heart Centre SingaporeBoston Scientific CorporationRecruitingCoronary Artery CalcificationSingapore, Japan
-
Segeberger Kliniken GmbHCompleted
-
SS Annunziata Hospital, SaviglianoNot yet recruitingMyocardial Infarction | Coronary Artery Disease
-
University Hospital, ToulouseCompletedAngioplastySpain, Russian Federation, Italy, France, Austria, Germany, Greece, Poland
-
Beijing Anzhen HospitalBSC International Medical Trading (Shanghai) Co., Ltd.Completed
-
Spectrumedics Medical Technology(Shanghai)Co.,LtdNot yet recruiting